Cited by 23Reproductive Health and ContraceptionHealth Systems, Economic Evaluations, Quality of LifeReproductive System and Pregnancy

Cost-effectiveness of curettage vs. expectant management in women with an incomplete evacuation after misoprostol treatment for first-trimester miscarriage: a randomized controlled trial and cohort study

Open access
Lemmers, Marike, Verschoor, Marianne A.C., Bossuyt, Patrick M., Huirne, Judith A.F., Spinder, Teake, Nieboer, Theodoor E., Bongers, Marlies Y., Janssen, Ineke A.H. +5 more·2018·Acta Obstetricia et Gynecologica Scandinavica

Abstract

INTRODUCTION: Curettage is more effective than expectant management in women with suspected incomplete evacuation after misoprostol treatment for first-trimester miscarriage. The cost-effectiveness of curettage vs. expectant management in this group is unknown. MATERIAL AND METHODS: From June 2012 until July 2014 we conducted a randomized controlled trial and parallel cohort study in the Netherlands, comparing curettage with expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for first-trimester miscarriage. Successful treatment was defined as a sonographic finding of an empty uterus 6 weeks after study entry, or an uneventful course. Cost-effectiveness and cost-utility analyses were performed. We included costs of healthcare utilization, informal care and lost productivity. Cost-effectiveness planes and cost-effectiveness acceptability curves were estimated using bootstrapping. RESULTS: We included 256 women from 27 hospitals; 95 curettage and 161 expectant management. Treatment was successful in 96% of the women treated with curettage vs. 83% of the women after expectant management (mean difference 13%, 95% confidence interval 5-20). Mean costs were significantly higher in the curettage group (mean difference €1157; 95% C confidence interval €955-1388). The incremental cost-effectiveness ratio for curettage vs. expectant management was €8586 per successfully treated woman. The cost-effectiveness acceptability curve showed that at a willingness-to-pay of €18 200/extra successfully treated women, the probability that curettage is cost-effective is 95%. CONCLUSIONS: Curettage is not cost-effective compared with expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment. This indicates that curettage in this group should be restrained.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/aogs.13283

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Direct health service costs for medical management ranged from £298 in a US study to £1421 in a UK study.

    “Direct health service costs for medical management ranged from £298 in a study from the United States 120 through to £1421 in a UK study. 113”

    From Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss (2021) · cites this paper as [113]

    Citation 113 is attached to the £1421 UK-study figure, not the £298 US-study figure. The Material and methods section says costs were estimated using Dutch guidelines and reported in 2014 euros; the Discussion also describes Dutch healthcare practice. This paper therefore does not report the attributed cost from a UK study. (LLM, conf=0.87)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • In the MIST trial economic evaluation, the mean value of work absences due to miscarriage was £431, with no significant difference between expectant, medical, and surgical management.

    “The mean value of work absences was estimated at £431 with no significant difference in values observed between the three management methods evaluated (expectant, management, surgical).”

    From Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss (2021) · cites this paper as [113]

    The Results (page unavailable) report no statistically significant difference in lost-productivity costs between curettage and expectant management. But this is an evaluation alongside the MisoREST trial, not the MIST trial; it compares two groups, reports costs in euros, and does not give a mean work-absence value of £431 or a three-way comparison with medical management. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Assuming economic consequences of miscarriage are felt only over the short term, combining national prevalence data for England with estimates of hospital and community health and social services costs, costs to patients, and broader societal costs associated with lost productivity generates an annual national estimate of economic burden of £471 million.

    “For example, assuming that the economic consequences of miscarriage are felt only over the short term and combining national prevalence data for England with estimates of costs of hospital and community health and social services, 113 costs to patients 127 and broader societal costs associated with lost productivity 113 generates an annual national estimate of economic burden of £471 million.”

    From Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss (2021) · cites this paper as [113]

    Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Most published studies aimed to provide information about options less costly than current practice or to probe the value of adjuncts to current practice.

    “Most published studies have aimed to provide information about options that are less costly than current practice, 111-118 or to probe the value of adjuncts to current practice. 119”
  • Unit cost estimates in published studies have been derived from primary research methods and administrative tariffs.

    “Unit costs estimates have been derived from a number of sources, including primary research methods 113,115,116 and administrative tariffs. 120,121”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lemmers, M., Verschoor, M. A. C., Bossuyt, P. M., Huirne, J. A. F., Spinder, T., Nieboer, T. E., Bongers, M. Y., Janssen, I. A. H., Van Hooff, M. H. A., Mol, B. W. J., Ankum, W. M., Bosmans, J. E., & on behalf of the MisoREST study group
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Medisch Centrum Leeuwarden (NL)
  • Radboud University Medical Center (NL)
  • Maastricht University (NL)
  • Groene Hart Ziekenhuis (NL)
  • Department of Obstetrics and Gynecology Sint Franciscus Gasthuis Rotterdam the Netherlands
  • South Australian Health and Medical Research Institute (AU)
  • Amsterdam Public Health (NL)
Corresponding author
Lemmers, Marike
Venue
Acta Obstetricia et Gynecologica Scandinavica
Publisher
Wiley
Published
2018-01-19
Volume
97
Issue
3
Pages
294-300
ISSN
  • 0001-6349 (ISSN-L)
  • 1600-0412
OpenAlex
W2780780487
Cited by
23
References
28
Citations by year
2026: 3 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 5 · 2019: 4
FWCI
1.03
Type
journal article
Language
en
Open access
Locations
  • Acta Obstetricia Et Gynecologica Scandinavica (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • VU Research Portal (publishedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
Funders
ZonMw (80‐82310‐97‐12066)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
Keywords
curettage, expectant management, incomplete evacuation, first-trimester miscarriage, misoprostol, cost-effectiveness, cost-utility analysis, cost-effectiveness acceptability curves, incremental cost-effectiveness ratio, health care costs, productivity loss
MeSH terms
Abortifacient Agents, Nonsteroidal, Abortion, Incomplete, Adult, Combined Modality Therapy, Cost-Benefit Analysis, Curettage, Female, Follow-Up Studies, Humans, Netherlands, Pregnancy, Pregnancy Trimester, First, Prospective Studies, Misoprostol, Treatment Outcome, Health Care Costs, Watchful Waiting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review